Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

A 22-year-old experiencing hair loss, initially attributed to stress, found temporary relief with minoxidil but faced increased shedding after stopping and restarting the treatment. The advice given suggests the hair loss may be due to androgenic alopecia rather than stress, recommending consistent use of minoxidil and considering finasteride, with a suggestion to seek a second opinion from another dermatologist.

Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.

The conversation discusses androgenetic alopecia (AGA) and questions why treatments focus on lowering DHT levels instead of building resistance to it. It also touches on hair transplantation techniques using body hair.

A 26-year-old man from France started experiencing hair loss in September 2020 and began using finasteride in June 2021, reporting some improvement after three months without side effects. He plans to continue finasteride for a year before considering additional treatments like minoxidil or dermarolling.